
¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín
Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.
Tratamiento de enfermedades neurodegenerativas asociadas a la edad
Resumen
Tipo:
Oferta Tecnológica
Referencia:
TODE20160803001
Publicado:
08/08/2016
Caducidad:
08/08/2017
Resumen:
Dos hospitales universitarios alemanes han desarrollado un nuevo enfoque para la prevención del daño neuronal inflamatorio en el curso de la degeneración macular u otras enfermedades neurodegenerativas. Esta tecnología previene la producción de citoquinas proinflamatorias y especies reactivas de oxígeno mediante la aplicación de ácido polisiálico de bajo peso molecular (PSA-20). Los estudios in vitro han demostrado que el PSA-20 previene la activación de macrófagos y microglías e inhiben la producción de citoquinas proinflamatorias citotóxicas y especies reactivas de oxígeno. Se buscan empresas o institutos de investigación del sector farmacéutico con el fin de establecer acuerdos de investigación y licencia.
Details
Tittle:
Treatment of age-related neurodegenerative diseases
Summary:
Two German university hospitals invented a novel approach for the prevention of inflammatory neuronal damage in the course of age-related macular degeneration or other neurodegenerative diseases. The university hospitals offer a research cooperation that can be combined with a licence agreement to companies or institutes in the pharmaceutical sector.
Description:
There is no satisfactory therapy to prevent the loss of synapses, axons or neurons in neurodegenerative diseases, such as age-related macular degeneration (AMD), multiple sclerosis and Alzheimer´s disease. Several studies demonstrate that this neuronal damage is partly mediated by pro-inflammatory cytokines and reactive oxygen species released by tissue macrophages and microglia.
The present invention of two German university hospitals prevents the production of pro-inflammatory cytokines and reactive oxygen species through the application of low molecular weight polysialic acid PSA-20.
In vitro studies showed that PSA-20 prevents the activation of human macrophages and human microglia thereby inhibiting the production of cytotoxic pro-inflammatory cytokines and reactive oxygen species. It has been shown, that this anti-inflammatory effect is mediated through the human lineage specific receptor Siglec-11. Furthermore, in vivo studies revealed that the administration of PSA-20 suppresses the activation of retinal microglia and the vascular leakage in an animal model of AMD and reduces the disease symptoms in an animal model of multiple sclerosis. Thus, PSA-20 represents an ideal candidate for the treatment of neurodegenerative diseases of the brain and retina.
The university hospitals offer a research cooperation that can be combined with a licence agreement to companies or institutes in the pharmaceutical sector. The research cooperation will be dedicated to enhance the PSA-20 treatment of dry AMD.
The present invention of two German university hospitals prevents the production of pro-inflammatory cytokines and reactive oxygen species through the application of low molecular weight polysialic acid PSA-20.
In vitro studies showed that PSA-20 prevents the activation of human macrophages and human microglia thereby inhibiting the production of cytotoxic pro-inflammatory cytokines and reactive oxygen species. It has been shown, that this anti-inflammatory effect is mediated through the human lineage specific receptor Siglec-11. Furthermore, in vivo studies revealed that the administration of PSA-20 suppresses the activation of retinal microglia and the vascular leakage in an animal model of AMD and reduces the disease symptoms in an animal model of multiple sclerosis. Thus, PSA-20 represents an ideal candidate for the treatment of neurodegenerative diseases of the brain and retina.
The university hospitals offer a research cooperation that can be combined with a licence agreement to companies or institutes in the pharmaceutical sector. The research cooperation will be dedicated to enhance the PSA-20 treatment of dry AMD.
Advantages and Innovations:
This invention, the application of PSA-20, is a novel approach for the prevention of inflammatory neuronal damage caused neurodegenerative diseases of the brain and retina.
The use of PSA-20 prevents:
- the production of reactive oxygen species and of pro-inflammatory cytokines
- the activation of microglia and the vascular leakage in an animal model of age related macular degeneration
- disease symptoms in an animal model of multiple sclerosis.
In addition to that PSA-20 has a relative high therapeutic index on cultured human cells.
The use of PSA-20 prevents:
- the production of reactive oxygen species and of pro-inflammatory cytokines
- the activation of microglia and the vascular leakage in an animal model of age related macular degeneration
- disease symptoms in an animal model of multiple sclerosis.
In addition to that PSA-20 has a relative high therapeutic index on cultured human cells.
Stage of Development:
Under development/lab tested
IPs:
Secret Know-how
Partner sought
Type and Role of Partner Sought:
The university hospitals offer a research cooperation that can be combined with a licence agreement to companies or institutes in the pharmaceutical sector. The research cooperation will be dedicated to enhance the PSA-20 treatment of dry AMD.
Client
Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
German
German
Keywords
Technology Keywords:
06002002 Biología celular y molecular
06001014 Neurología, investigación cerebral
06001015 Productos farmacéuticos / medicamentos
06001014 Neurología, investigación cerebral
06001015 Productos farmacéuticos / medicamentos